Trial
NCT00973024
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators
—
Condition
Low Back Pain
Intervention
JNJ-42160443 3 mg
Why stopped
Based on lack of efficacy in PAI2003, sponsor made the decision to discontinue the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-06